Literature DB >> 18069918

Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion.

M Muñoz1, C Breymann, J A García-Erce, S Gómez-Ramírez, J Comin, E Bisbe.   

Abstract

Anaemia is a common condition among patients admitted to hospital medicosurgical departments, as well as in critically ill patients. Anaemia is more frequently due to absolute iron deficiency (e.g. chronic blood loss) or functional iron deficiency (e.g. chronic inflammatory states), with other causes being less frequent. In addition, preoperative anaemia is one of the major predictive factors for perioperative blood transfusion. In surgical patients, postoperative anaemia is mainly caused by perioperative blood loss, and it might be aggravated by inflammation-induced inhibition of erythropoietin and functional iron deficiency (a condition that cannot be corrected by the administration of oral iron). All these mechanisms may be involved in the anaemia of the critically ill. Intravenous iron administration seems to be safe, as very few severe side-effects were observed, and may result in hastened recovery from anaemia and lower transfusion requirements. However, it is noteworthy that many of the recommendations given for intravenous iron treatment are not supported by a high level of evidence and this must be borne in mind when making decisions regarding its application to a particular patient. Nonetheless, this also indicates the need for further large, randomized controlled trials on the safety and efficacy of intravenous iron for the treatment of anaemia in different clinical settings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18069918     DOI: 10.1111/j.1423-0410.2007.01014.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  23 in total

Review 1.  On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.

Authors:  Manuel Muñoz; José Antonio García-Erce; Jorge Cuenca; Elvira Bisbe; Enrique Naveira
Journal:  Blood Transfus       Date:  2011-11-30       Impact factor: 3.443

2.  Double bull's eye for post-operative intravenous iron in patient blood management: better outcome and cost-effective.

Authors:  Giancarlo M Liumbruno; Gioia Grazzini
Journal:  Blood Transfus       Date:  2013-12-04       Impact factor: 3.443

3.  eComment. The problem of anaemia correction in cardiac surgery patients.

Authors:  Leo A Bockeria; Olga Bockeria; Maria Sokolskaya; Sergei Donakanian
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-12

Review 4.  Perioperative anemia management in colorectal cancer patients: a pragmatic approach.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Elisa Martín-Montañez; Michael Auerbach
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

5.  Intravenous iron therapy: how far have we come?

Authors:  Rodolfo Delfini Cançado; Manuel Muñoz
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 6.  An update on iron physiology.

Authors:  Manuel Muñoz; Isabel Villar; José Antonio García-Erce
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

Review 7.  Intravenous iron in inflammatory bowel disease.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; José Antonio García-Erce
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

8.  Emerging causes of iron deficiency anemia refractory to oral iron supplementation.

Authors:  Sean Warsch; John Byrnes
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-08-06

9.  Treatment of Iron Deficiency in Women.

Authors:  C Breymann; T Römer; J W Dudenhausen
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

Review 10.  Current misconceptions in diagnosis and management of iron deficiency.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Martin Besser; José Pavía; Fernando Gomollón; Giancarlo M Liumbruno; Sunil Bhandari; Mercé Cladellas; Aryeh Shander; Michael Auerbach
Journal:  Blood Transfus       Date:  2017-09       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.